Key clinical point: Patients with metastatic non–small cell lung cancer who enrolled in clinical trials at one center had a near 50% lower risk of death versus nonenrollees treated at the same center.
Major finding: Median survival was 838 days for the clinical trial enrollees versus 454 days for nonenrollees, with a risk of death 47% lower for enrollees relative to nonenrollees after adjustment for patient- and tumor-specific variables.
Study details: A retrospective study including 371 patients diagnosed with metastatic non–small cell lung cancer between 2001 and 2015.
Disclosures: The study authors reported disclosures related to numerous pharmaceutical companies.
Merkhofer C et al. QCS 2019, Abstract 137.